Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Hisamitsu Pharmaceutical Co., Inc. (4530:JPX), powered by AI.
Hisamitsu Pharmaceutical Co., Inc. is currently trading at ¥6,040. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Hisamitsu Pharmaceutical Co., Inc. on Alpha Lenz.
Hisamitsu Pharmaceutical Co., Inc.'s P/E ratio is 20.4.
“Hisamitsu Pharmaceutical Co., Inc. trades at a P/E of 20.4 (fair value) with solid ROE of 8.0%.”
Ask for details →Hisamitsu Pharmaceutical Co., Inc. is a pharmaceutical company known for developing and producing over-the-counter medicines and therapeutic products, with a focus on topical treatments. Established in Japan, the company's primary purpose is to enhance quality of life by providing pain relief and therapeutic solutions, particularly through innovative transdermal delivery systems. They are renowned for their pioneering work in patches, such as Salonpas, which offer a non-invasive method for delivering medication directly through the skin. Hisamitsu's products are widely used across various sectors including healthcare environments, individual consumers, and sports medicine. The company has a significant impact on both local and global markets, contributing to advancements in pain management and healthcare technology. Hisamitsu's focus on research and development keeps it at the forefront of pharmaceutical innovation, maintaining its reputation as a leader in therapeutic skin care solutions.
“Hisamitsu Pharmaceutical Co., Inc. trades at a P/E of 20.4 (fair value) with solid ROE of 8.0%.”
Ask for details →Hisamitsu Pharmaceutical Co., Inc. (ticker: 4530) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 2,799 employees. Market cap is $444.6B.
The current price is 6,040 with a P/E ratio of 20.44x and P/B of 1.61x.
ROE is 8.03% and operating margin is 12.11%. Annual revenue is $156.0B.